Myriad Genetics presents advances in precision

SALT LAKE CITY, May 26, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will present multiple studies at the 2022 American Society of Clinical Oncology (ASCO). Annual meeting highlighting the value of genetic knowledge in guiding and clarifying cancer treatment and risk assessment.

The presentations underscore Myriad’s commitment to work with oncologists and other healthcare partners to advance healthcare equity and provide data-driven insights to guide clinical care and improve outcomes. They follow the recent launch of Precise™ Oncology Solutions, a comprehensive suite of solutions that provide germline testing, tumor profiling and companion diagnostic options, including homologous recombination deficiency (HRD) assessment. The suite offers a streamlined testing experience designed to help oncologists recommend personalized treatment plans for their patients.

Precise Oncology Solutions currently includes Myriad’s Precise™ Tumor Test, MyRisk™ Hereditary Cancer Test and its two FDA-cleared companion diagnostic tests: MyChoice® CDx and BRACAnalysis CDx®. A new Precise Treatment Registry combines germline, somatic and HRD gene data to accelerate the pace of precision cancer research and equitable advances in patient care. Additionally, Myriad recently announced that it will expand its strategic partnership with Intermountain Precision Genomics, a service of Intermountain Healthcare, to offer a liquid biopsy therapy screening test as part of its growing oncology portfolio in 2023.

Also at ASCO, Myriad will highlight a validation study for its market-leading MyRisk Hereditary Cancer Test with RiskScore®, the first polygenic breast cancer risk assessment clinically and analytically validated for women of all ancestry. Providers can gain important insights to identify women at increased risk of breast cancer who do not have a deleterious mutation in known breast cancer genes, such as: BRCA1.

“Cancer prevention and treatment are most effective when based on genetic knowledge,” said Thomas Slavin, MD, chief medical officer, Myriad Genetics. “Our recent portfolio additions and presentations at ASCO underscore our efforts to continually grow and innovate to better empower physicians with comprehensive data-driven answers that inform treatment decisions, reduce healthcare disparities and improve outcomes for all patients.”

Data from Myriad to be presented at the meeting:

A Breast Cancer (BC) Risk Model Using Tyrer-Cuzick Version 8 (TCv8) and a Polygenic Risk Score for Different Ancestry (Abstract #366104)
Session type: poster session
Date: Monday 6 June 2022
Time: 8:00 a.m. – 11:00 a.m. CDT

This is the first breast cancer risk model to include breast density, family history and a polygenic risk score (PRS) based on genetically determined ancestry that has been validated across populations. The addition of PRS significantly improved risk stratification over TCv8 alone, potentially allowing for a more personalized approach to breast cancer risk reduction.

Lineage-Specific Risk of Triple Negative Breast Cancer (TNBC) Associated with Germline Pathogenic (PV) Variants in Hereditary Cancer Predisposition Genes (Abstract #377784)
Session Type: Poster Discussion
Date: Monday 6 June 2022
Time: 16:30-18:00; 1:15 p.m. – 4:15 p.m. CDT

Pathogenic variants emerged in this population of women undergoing multigene panel testing BRCA1, BRCA2, PALB2, RAD51C, RAD51Dand BARD1 have been associated with a significant risk of triple negative breast cancer (TNBC). There were no significant differences in TNBC risks associated with pathogenic variants between ancestors. TNBC has been reported more frequently in women of African descent.

Exploring homologous recombination deficit thresholds for predicting response to platinum-based treatment in triple-negative breast cancer (Abstract #364894)
Session type: poster session
Date: Monday 6 June 2022
Time: 8:00 a.m. – 11:00 a.m. CDT

This exploratory analysis evaluated the ability of ≥33 or ≥42 genomic instability score (GIS) thresholds to predict response to platinum-based treatment in patients with triple-negative breast cancer. This study of 204 tumors mixed BRCA wild type, BRCA Mutations and unknown showed that a GIS ≥ 33 may be the most appropriate threshold to predict response to platinum-based treatment in patients with TNBC; however, a prospective study is needed.

Compliance with EndoPredict Test Results for Extended Endocrine Therapy Management in the Prospective EndoPredict Extended Endocrine Trial (EXET) (Abstract #371368)
Session type: poster session
Date: Monday 6 June 2022
Time: 8:00 a.m. – 11:00 a.m. CDT

Even adjusting for other clinical factors such as nodal status, tumor grade, age at diagnosis and other variables, Myriad’s EndoPredict® breast cancer prognostic test provided significant information for clinical decisions about advanced endocrine therapy in this patient cohort.

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and wellness for all. Myriad develops and markets genetic testing that helps assess the risk of developing a disease or disease progression and to guide treatment decisions in all medical specialties where genetic knowledge can significantly improve patient care and reduce healthcare costs. Fast Company called Myriad among the The most innovative companies in the world for 2022. Visit www.myriad.com for more information.

Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, Health.Illuminated., RiskScore, Prolaris , GeneSight and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. All rights reserved.

Safe Harbor Declaration
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the Company’s presentation of several studies at the 2022 ASCO Annual Meeting, the expansion of the Company’s strategic partnership with Intermountain Precision Genomics and a screening test for liquid biopsy therapy in 2023, the Company’s plan to highlight a validation study for its MyRisk Hereditary Cancer Test with RiskScore at the 2022 ASCO Annual Meeting, and the Company’s strategic imperatives under the “About Myriad Genetics” heading. These “forward-looking statements” represent management’s current expectations regarding future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to: uncertainties related to COVID-19, including its potential impact on the Company’s operations and demand for its products and services, and the Company’s ability to run its business efficiently and flexibly; the risk that sales and margins of the Company’s existing molecular diagnostics tests will decline or that the Company may not be able to operate its business on a profitable basis; risks related to the Company’s ability to generate sufficient revenue from its existing product portfolio or from the introduction and commercialization of new tests; risks related to changes in the coverage and reimbursement levels of government or private insurers for the Company’s tests or the Company’s ability to receive reimbursement for its new tests at comparable levels to its existing tests; risks related to increased competition and the development of new competing tests and services; the risk that the Company may not be able to develop or achieve commercial success for additional molecular diagnostic tests in a timely manner or at all; the risk that the Company will not be successful in entering new markets for its molecular diagnostic tests, including the Company’s ability to successfully generate revenue outside of the United States; the risk that licenses for the technology underlying the Company’s molecular diagnostic tests and any future tests may be terminated or cannot be maintained on satisfactory terms; risks related to delays or other issues in the operation and construction of the Company’s laboratory test facilities; risks related to public concern about genetic testing in general, or the Company’s testing in particular; risks related to regulatory requirements or enforcement in the United States and other countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to the Company’s ability to obtain new business collaborations or licenses and to acquire or develop new technology or businesses on satisfactory terms, if at all; risks related to the Company’s ability to successfully integrate and take advantage of technologies or companies that it licenses, acquires or develops; risks associated with the Company’s projections of potential market opportunities for the Company’s current and future products; the risk that the Company or its licensors may be unable to protect the proprietary technologies underlying the Company’s tests or that third parties may infringe the proprietary technologies; the risk of patent infringement claims or challenges to the validity of the Company’s patents; risks related to changes in intellectual property laws affecting the Company’s molecular diagnostic tests or patents or their enforcement in the United States and other countries; risks related to security breaches, data loss and other disruptions, including from cyber attacks; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that the company may not be able to meet financial operating agreements under the company’s credit or loan agreements; risks related to the material weakness associated with general information technology controls, including the impact thereof and the Company’s remediation plan, and its ability to achieve and maintain effective disclosure controls and processes and internal controls over financial reporting; risks related to current and future litigation, including product or professional liability claims; and other factors discussed under the heading “Risk Factors” in Item 1A of the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on February 25, 2022, and any updates to these risk factors filed by have been included from time to time in the Company’s quarterly reports on Form 10-Q or current reports on Form 8-K.

About Stephanie McGehee

Check Also

Flooding rocks the Yellowstone region, leaving many stranded

Breadcrumb Trail Links PMN business Author of the article: The Associated Press Amy Beth Hanson …